Human Growth Hormone Market
Global Human Growth Hormone Market Size, Share & Trends Analysis Report by Application (Growth Hormone Deficiency, Prader-Willi Syndrome, Turner Syndrome, Chronic Kidney Disease, Small for Gestational Stage and Others), By Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral) Forecast Period 2019-2025 Update Available - Forecast 2024-2030
The human growth hormone market is anticipated to grow at a significant CAGR during the forecast period. The market growth is attributed to the growing demand for human growth hormone for cosmetic treatment. Human growth hormone such as IGF-1 is widely used as an anti-aging treatment. This hormone can increase the thickness and flexibility of skin and reduction of wrinkles caused by ultraviolet rays. Hence, the growing aging population is expected to fuel the demand for human growth hormone globally. Other factors such as advancement in technology such as recombinant DNA technology for the development of human growth hormone drugs and increasing investment and collaborating amongmajor players for the R&D of human growth hormone drugs are also fueling the market growth.
In addition, rising incidences of human growth hormone deficiency diseases propel the growth of the human growth hormone market during the forecast period. According to the National Organization for Rare Disorders, Inc.(NORD), growth hormone deficiency diseases occur in roughly 1 in 7,000 births. The condition is also a symptom of several genetic diseases, including Noonan syndrome, Turner syndrome and Prader-Willi syndrome.Owing to growing cases of these growth hormone deficiency diseases, the market for human growth hormone is expected to grow. FDA has approved various treatments for growth hormone deficiency. For instance,Nutropin, Humatrope, Genotropin, Saizen, Norditropin, Tev-Tropin, and Omnitropeare approved by the FDA for the treatment of growth hormone deficiency.
However,the high cost of these products is expected to limit the growth of the market. Along with it, stringent regulatory approvals and adverse effects associated with the use of synthetic human growth hormones are the factors hampering the growth of the human growth hormone market.Many companies are investing in R&D of long-acting hormonal therapy which is expected to create enormous opportunities for market growth. For instance, in 2016, Novo Nordisk invested multimillion-dollar in Lebanon to enhance the supply in a rural community. These produce medicines to treat hemophilia and growth disorders.
Segmental Outlook
The global human growth hormone market is segmented on the basis of the application and route of administration. Based on the application, the market is sub-segmented into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, chronic kidney disease,small for gestational stage and others. Turner syndrome segment is expected to have a significant market share in the human growth hormone due to its demand attributed to the growing incidence of Turner syndrome across the globe. For instance, according to NORD, it is estimated that approximately more than 70,000 women and girls have turner syndrome in the US. Based on the route of administration, the market is sub-segmented into intravenous, intramuscular, subcutaneous and oral.
Regional Outlook
The market is further segmented based on geography including North America, Europe, Asia-Pacific and Rest of the World. North America is anticipated to have the largest market share in the human growth hormone market during the forecast period-owing to increased consumption of human growth hormone therapies in the region for the cosmetic treatment and several disorders such as Turner syndrome. Moreover, ease of availability of artificial growth hormones, rise in R&D investments and new drug development for the treatment of diseases that propels the growth of the human growth hormone industry in the region.
Global Human Growth Hormone Market Growth, by Region 2019-2025
Asia-Pacific will augment with the fastest rate in the Human Growth Hormone market
The market in Asia-Pacific is expected to be the fastest-growing region mainly due to the increase in the incidence of human growth hormone deficiency in the region. Additionally, an increase in healthcare expenditure, major players are investing in the R&D activities for recombinant human growth hormones and a rise in disposable income are the factors that are fuelling the growth of the market in the region.
Market Players Outlook
The key players of the human growth hormone market include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly & Co., EMD Serono, Inc. (A division of Merck KGaA, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd., Ferring Pharmaceuticals, Inc., Ipsen Group, and Teva Pharmaceutical Industries, Ltd. The players are continuously adopting various strategies in order to compete in the market. For instance, in March 2019, Ipsen launches a new pre-filled syringe for its rare disease blockbuster Somatuline in the EU. The new design was based on studies that, involving patients, their caregivers, nurses and other healthcare professionals that results in to inform and test improvements to the existing pre-filled syringe.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global human growth hormone market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Novo Nordisk A/S
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Pfizer, Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Eli Lilly& Co.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. EMD Serono, Inc. (A division of Merck KGaA)
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Human Growth Hormone Market by Application
5.1.1. Growth Hormone Deficiency
5.1.2. Prader-Willi Syndrome
5.1.3. Chronic Kidney Disease
5.1.4. Turner Syndrome
5.1.5. Small for gestational stage
5.1.6. Others (Short Bowel Syndrome)
5.2. Global Human Growth Hormone Market by Route of Administration
5.2.1. Intravenous
5.2.2. Intramuscular
5.2.3. Subcutaneous
5.2.4. Oral
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Anhui Anke Biotechnology (Group)Co., Ltd.
7.2. Ascendis PharmaA/S
7.3. Eli Lilly & Co.
7.4. EMD Serono, Inc. (A division of Merck KGaA)
7.5. F. Hoffmann-La Roche, Ltd.
7.6. Ferring Pharmaceuticals, Inc.
7.7. Genentech, Inc.
7.8. GeneScience Pharmaceuticals Co., Ltd.
7.9. Ipsen Group
7.10. LG Chem Life Sciences Co.
7.11. Lifetech Labs
7.12. Novartis AG
7.13. Novo Nordisk A/S
7.14. Pfizer, Inc.
7.15. Teva Pharmaceutical Industries, Ltd.
1. GLOBAL HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
2. GLOBAL GROWTH HORMONE DEFICIENCY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL PRADER-WILLI SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL TURNER SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL CHRONIC KIDNEY DISEASEMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL SMALL FOR GESTATIONAL STAGE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2018-2025 ($ MILLION)
9. GLOBAL INTRAVENOUS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL INTRAMUSCULAR MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL SUBCUTANEOUS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
12. GLOBAL ORAL MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
13. GLOBAL HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
14. NORTH AMERICANHUMAN GROWTH HORMONEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
15. NORTH AMERICAN HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
16. NORTH AMERICAN HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2018-2025 ($ MILLION)
17. EUROPEANHUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
18. EUROPEANHUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
19. EUROPEANHUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2018-2025 ($ MILLION)
20. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
21. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
22. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2018-2025 ($ MILLION)
23. REST OF THE WORLD HEALTH INTELLIGENT VIRTUA ASSISTAN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
24. REST OF THE WORLD HEALTH INTELLIGENT VIRTUA ASSISTANT MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2018-2025 ($ MILLION)
1. GLOBAL HUMAN GROWTH HORMONE MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
2. GLOBAL HUMAN GROWTH HORMONE MARKET SHARE BY ROUTE OF ADMINISTRATION, 2018 VS 2025 (%)
3. GLOBAL HUMAN GROWTH HORMONE MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
4. THE US HUMAN GROWTH HORMONEMARKET SIZE, 2018-2025 ($ MILLION)
5. CANADA HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
6. UK HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
7. FRANCE HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
8. GERMANY HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
10. SPAIN HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
11. ROE HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
12. INDIA HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
13. CHINA HUMAN GROWTH HORMONEMARKET SIZE, 2018-2025 ($ MILLION)
14. JAPAN HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF THE WORLD HUMAN GROWTH HORMONE MARKET SIZE, 2018-2025 ($ MILLION)
